MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

January 19, 2017

NEW YORK, JANUARY 20, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) began a new clinical trial this week in Uzbekistan to develop a radically improved course of treatment for drug-resistant tuberculosis (DR-TB).

The trial aims to find a treatment regimen for DR-TB that is drastically shorter, more effective, and causes fewer side effects than the current treatment options.

December 20, 2016

NEW YORK, DECEMBER 20, 2016—After 14 years of Chagas diagnoses, treatment and prevention efforts in Bolivia, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) ended its Chagas operations today by presenting Bolivia’s Ministry of Health with an operating manual for managing Chagas disease in rural areas.

May 12, 2016

The World Health Organization has just recommended that countries move toward shorter treatment regimens for some people with drug-resistant tuberculosis (DR-TB), including people co-infected with HIV, children, and people with simple MDR-TB who have not been treated before or and have no known resistance to any of the drugs in the regimen. This recommendation comes following results from a number of large observation cohort studies using the shortened regimen.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

August 06, 2015

In Uzbekistan’s Autonomous Republic of Karakalpakstan, Doctors Without Borders/Médecins Sans Frontières (MSF) runs a tuberculosis (TB) program in collaboration with the Ministry of Health, helping patients manage the side effects of their drug regimens and providing psychosocial support to improve treatment adherence. Here, MSF medical team leader Tetyana Pylypenko discusses MSF’s

April 14, 2015

SUCRE, BOLIVIA/NEW YORKDoctors Without Borders/Médecins Sans Frontières (MSF) is launching a new project to ensure that people can be diagnosed and treated for Chagas disease in the town of Monteagudo, in the Chuquisaca department of southern Bolivia. In partnership with local health care institutions, the international medical humanitarian organization will develop a comprehensive care model for primary and secondary care that will be integrated into the existing health care system.

December 17, 2013

Tuberculosis (TB) and its drug-resistant forms are a global health threat to which children are particularly vulnerable.

July 11, 2013

MSF doctor Emily Wise blogs from Karakalpakstan, Uzbekistan, where MSF is working to treat tuberculosis patients.

Pages

January 19, 2017

NEW YORK, JANUARY 20, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) began a new clinical trial this week in Uzbekistan to develop a radically improved course of treatment for drug-resistant tuberculosis (DR-TB).

The trial aims to find a treatment regimen for DR-TB that is drastically shorter, more effective, and causes fewer side effects than the current treatment options.

December 20, 2016

NEW YORK, DECEMBER 20, 2016—After 14 years of Chagas diagnoses, treatment and prevention efforts in Bolivia, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) ended its Chagas operations today by presenting Bolivia’s Ministry of Health with an operating manual for managing Chagas disease in rural areas.

May 12, 2016

The World Health Organization has just recommended that countries move toward shorter treatment regimens for some people with drug-resistant tuberculosis (DR-TB), including people co-infected with HIV, children, and people with simple MDR-TB who have not been treated before or and have no known resistance to any of the drugs in the regimen. This recommendation comes following results from a number of large observation cohort studies using the shortened regimen.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

August 06, 2015

In Uzbekistan’s Autonomous Republic of Karakalpakstan, Doctors Without Borders/Médecins Sans Frontières (MSF) runs a tuberculosis (TB) program in collaboration with the Ministry of Health, helping patients manage the side effects of their drug regimens and providing psychosocial support to improve treatment adherence. Here, MSF medical team leader Tetyana Pylypenko discusses MSF’s

April 14, 2015

SUCRE, BOLIVIA/NEW YORKDoctors Without Borders/Médecins Sans Frontières (MSF) is launching a new project to ensure that people can be diagnosed and treated for Chagas disease in the town of Monteagudo, in the Chuquisaca department of southern Bolivia. In partnership with local health care institutions, the international medical humanitarian organization will develop a comprehensive care model for primary and secondary care that will be integrated into the existing health care system.

December 17, 2013

Tuberculosis (TB) and its drug-resistant forms are a global health threat to which children are particularly vulnerable.

July 11, 2013

MSF doctor Emily Wise blogs from Karakalpakstan, Uzbekistan, where MSF is working to treat tuberculosis patients.

Pages